Tuesday, 19 Mar 2019

You are here

Lancet Tackles the Global Challenge of Low Back Pain

Lancet has several reports on low back pain (LBP) as a major problem worldwide, largely because of the aging population.

Low back pain is the leading cause of disability worldwide.

Unfortunately, with most LBP it is impossible to identify a specific nociceptive cause. Only a small proportion of people have a well understood pathological or mechanical cause for their pain. (Citation source: http://bit.ly/2GxQdzd)

Disability from LBP has increased 54% between 1990 and 2015, especially in low-income and middle-income countries. Moreover disability related to LBP is projected to increase when resources are limited, or there is poor access to health and if sedentary lifestyle changes increase.

Some facts from these articles:

  • Low back pain was responsible for 60·1 million disability-adjusted life-years in 2015,
  • Disability is highest in working age groups worldwide, which is especially concerning in low-income and middle-income countries
  • Most LBP episodes are short-lasting with little or no consequence, but recurrent episodes are common
  • Lifestyle factors, such as smoking, obesity, and low levels of physical activity, relate to poorer general health
  • The global burden of LBP low back pain is projected to increase further especially in low-income and middle-income countries.

Clinical practice guidelines for LBP exist and many recommend a biopsychosocial framework that includes initial non-pharmacological treatment, education, self-management and resumption of normal activities and exercise.

Guidelines recommend prudent use of medication, imaging, and surgery. But these recommendations come from high-income countries, focused on treatments rather than prevention, and have limited data for cost-effectiveness.

What is needed are advances that align practice with the evidence, reduce the focus on spinal abnormalities, and ensure promotion of activity and function, including return to work.

The Lancet Low Back Pain working group have put forth a call for action that includes: (Citation source: http://bit.ly/2GCQJrF) 

  • Call on international and national political, medical and social policy leaders to adequately fund public health strategies focused on preventing low back pain from interfering with life, ensuring inclusion of disadvantaged and culturally diverse populations
  • The need to prioritise low back pain, together with other musculoskeletal conditions, as a public health problem
  • Develop and implement strategies to address modifiable risk factors for disabling low back pain
  • Develop and implement strategies to ensure early identification and adequate education of patients with low back pain at risk for persistence and recurrence
  • Promote active multidisciplinary rehabilitation to support return to work
  • Government, insurers, and commissioners should consider tackling conflicts of interest through regulation and contracts, including not paying for inappropriate tests and for unnecessary, ineffective, and harmful treatments
  • Existing and new tests and procedures for low back pain should be regulated in the same way as drugs; evidence should be available showing that they are safe, effective, and cost-effective before they get reimbursed within public health-care systems
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

New Sleep Medicine Guidelines for Obstructive Sleep Apnea

The American Academy of Sleep Medicine (AASM) has established new guidelines for the evaluation and treatment of sleep-disordered breathing in adults, specifically guiding the use of positive airway pressure (PAP) in the treatment of obstructive sleep apnea (OSA) in adults. 

Pain Drives the Use of Medical Marijuana

A report from the University of Michigan examined state-wide medical marijuana showing most of it is used for chronic pain.

The authors include Kevin Boehnke, Ph.D., Daniel J. Clauw, M.D., Rebecca L. Haffajee, Ph.D., and Saurav Gangopadhyay, M.P.H. undertook this investigation to to assess why people are using cannabis medically. 

Compounded Pain Creams - Expensive Placebos?

The Annals of Internal Medicine reports that the growth and use of compounded pain creams is unwarranted as they were no better than placebo in a randomized controlled trial, suggesting their higher costs are unjustifiable compared to other topical commercially available agents (lidocaine, diclofenac, capsaicin, etc.). (Citation source: https://buff.ly/2BkTj58)

Opioids Double Rates of Suicides and Overdoses

An article in the New England Journal of Medicine reports that the rates of suicide and drug overdoses has doubled in the last 17 years, and that opioids are largely to blame.

Using data from the Centers for Disease Control and Prevention databases, researchers show that the sheer number of deaths from suicides and unintentional overdoses together rose from 41,364 in the year 2000 to 110,749 in 2017.

Cryotherapy Never FDA Approved

Another injury related to whole body cryotherapy (WBC) has been reported by practitioners in Philadelphia, serving as yet another warning of WBC's potential to cause serious adverse effects.